Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor

BACKGROUND: Whether sodium glucose co-transporter 2 inhibitors (SGLT2i) are associated with a lower risk of cardiovascular as well as adverse lower limb events in patients with type-2 diabetes mellitus (T2DM) and concomitant peripheral artery disease (PAD) is unclear. We aimed to evaluate the risk o...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hsin-Fu, Chen, Shao-Wei, Liu, Jia-Rou, Li, Pei-Ru, Wu, Lung-Sheng, Chang, Shang-Hung, Yeh, Yung-Hsin, Kuo, Chi-Tai, Chan, Yi-Hsin, See, Lai-Chu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528264/
https://www.ncbi.nlm.nih.gov/pubmed/32998736
http://dx.doi.org/10.1186/s12933-020-01118-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528264/
https://www.ncbi.nlm.nih.gov/pubmed/32998736
http://dx.doi.org/10.1186/s12933-020-01118-0

Ejemplares similares